Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities
Background: Plasma IL-6 and YKL-40 are prognostic biomarkers for OS in patients with different types of solid tumors, but they have not been studied in patients before surgery of metastatic bone disease (MBD) of the extremities. The aim was to evaluate the prognostic value of plasma IL-6 and YKL-40...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/11/2833 |
id |
doaj-b29c3cbcb4d243cf84a1d1163cce07c2 |
---|---|
record_format |
Article |
spelling |
doaj-b29c3cbcb4d243cf84a1d1163cce07c22021-06-30T23:28:45ZengMDPI AGCancers2072-66942021-06-01132833283310.3390/cancers13112833Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the ExtremitiesMichala Skovlund Sørensen0Thomas Colding-Rasmussen1Peter Frederik Horstmann2Klaus Hindsø3Christian Dehlendorff4Julia Sidenius Johansen5Michael Mørk Petersen6Musculoskeletal Tumor Section, Department of Orthopedic Surgery, Rigshospitalet, University of Copenhagen, 2100 Copenhagen Ø, DenmarkMusculoskeletal Tumor Section, Department of Orthopedic Surgery, Rigshospitalet, University of Copenhagen, 2100 Copenhagen Ø, DenmarkMusculoskeletal Tumor Section, Department of Orthopedic Surgery, Rigshospitalet, University of Copenhagen, 2100 Copenhagen Ø, DenmarkPediatric Section, Department of Orthopedic Surgery, Rigshospitalet, University of Copenhagen, 2100 Copenhagen Ø, DenmarkStatistics and Data Analysis Danish Cancer Society Research Center, 2100 Copenhagen Ø, DenmarkDepartment of Medicine, Herlev and Gentofte Hospital, Copenhagen University Hospital, 2730 Herlev, DenmarkMusculoskeletal Tumor Section, Department of Orthopedic Surgery, Rigshospitalet, University of Copenhagen, 2100 Copenhagen Ø, DenmarkBackground: Plasma IL-6 and YKL-40 are prognostic biomarkers for OS in patients with different types of solid tumors, but they have not been studied in patients before surgery of metastatic bone disease (MBD) of the extremities. The aim was to evaluate the prognostic value of plasma IL-6 and YKL-40 in patients undergoing surgery for MBD of the extremities. Patients and Methods: A prospective study included all patients undergoing surgery for MBD in the extremities at a tertiary referral center during the period 2014–2018. Preoperative blood samples from index surgery were included. IL-6 and YKL-40 concentrations in plasma were determined by commercial ELISA. A total of 232 patients (median age 66 years, IQR 58–74; female 51%) were included. Results: Cox regression analysis was performed to identify independent prognostic factors for OS. IL-6 correlated with YKL-40 (rho = 0.46, <i>p</i> < 0.01). In univariate analysis (log<sub>2</sub> continuous variable) IL-6 (HR = 1.26, 95% CI 1.16–1.37), CRP (HR = 1.20, 95% CI 1.12–1.29) and YKL-40 (HR = 1.25, 95% CI 1.15–1.37) were associated with short OS. In multivariable analysis, adjusted for known risk factors for survival, only log<sub>2</sub>(IL-6) was independently associated with OS (HR = 1.24, 95% CI 1.08–1.43), whereas CRP and YKL-40 were not. Conclusion: High preoperative plasma IL-6 is an independent biomarker of short OS in patients undergoing surgery for MBD.https://www.mdpi.com/2072-6694/13/11/2833bone metastasesinflammatory responseIL-6prognostic biomarkersYKL-40 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Michala Skovlund Sørensen Thomas Colding-Rasmussen Peter Frederik Horstmann Klaus Hindsø Christian Dehlendorff Julia Sidenius Johansen Michael Mørk Petersen |
spellingShingle |
Michala Skovlund Sørensen Thomas Colding-Rasmussen Peter Frederik Horstmann Klaus Hindsø Christian Dehlendorff Julia Sidenius Johansen Michael Mørk Petersen Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities Cancers bone metastases inflammatory response IL-6 prognostic biomarkers YKL-40 |
author_facet |
Michala Skovlund Sørensen Thomas Colding-Rasmussen Peter Frederik Horstmann Klaus Hindsø Christian Dehlendorff Julia Sidenius Johansen Michael Mørk Petersen |
author_sort |
Michala Skovlund Sørensen |
title |
Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities |
title_short |
Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities |
title_full |
Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities |
title_fullStr |
Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities |
title_full_unstemmed |
Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities |
title_sort |
pretreatment plasma il-6 and ykl-40 and overall survival after surgery for metastatic bone disease of the extremities |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2021-06-01 |
description |
Background: Plasma IL-6 and YKL-40 are prognostic biomarkers for OS in patients with different types of solid tumors, but they have not been studied in patients before surgery of metastatic bone disease (MBD) of the extremities. The aim was to evaluate the prognostic value of plasma IL-6 and YKL-40 in patients undergoing surgery for MBD of the extremities. Patients and Methods: A prospective study included all patients undergoing surgery for MBD in the extremities at a tertiary referral center during the period 2014–2018. Preoperative blood samples from index surgery were included. IL-6 and YKL-40 concentrations in plasma were determined by commercial ELISA. A total of 232 patients (median age 66 years, IQR 58–74; female 51%) were included. Results: Cox regression analysis was performed to identify independent prognostic factors for OS. IL-6 correlated with YKL-40 (rho = 0.46, <i>p</i> < 0.01). In univariate analysis (log<sub>2</sub> continuous variable) IL-6 (HR = 1.26, 95% CI 1.16–1.37), CRP (HR = 1.20, 95% CI 1.12–1.29) and YKL-40 (HR = 1.25, 95% CI 1.15–1.37) were associated with short OS. In multivariable analysis, adjusted for known risk factors for survival, only log<sub>2</sub>(IL-6) was independently associated with OS (HR = 1.24, 95% CI 1.08–1.43), whereas CRP and YKL-40 were not. Conclusion: High preoperative plasma IL-6 is an independent biomarker of short OS in patients undergoing surgery for MBD. |
topic |
bone metastases inflammatory response IL-6 prognostic biomarkers YKL-40 |
url |
https://www.mdpi.com/2072-6694/13/11/2833 |
work_keys_str_mv |
AT michalaskovlundsørensen pretreatmentplasmail6andykl40andoverallsurvivalaftersurgeryformetastaticbonediseaseoftheextremities AT thomascoldingrasmussen pretreatmentplasmail6andykl40andoverallsurvivalaftersurgeryformetastaticbonediseaseoftheextremities AT peterfrederikhorstmann pretreatmentplasmail6andykl40andoverallsurvivalaftersurgeryformetastaticbonediseaseoftheextremities AT klaushindsø pretreatmentplasmail6andykl40andoverallsurvivalaftersurgeryformetastaticbonediseaseoftheextremities AT christiandehlendorff pretreatmentplasmail6andykl40andoverallsurvivalaftersurgeryformetastaticbonediseaseoftheextremities AT juliasideniusjohansen pretreatmentplasmail6andykl40andoverallsurvivalaftersurgeryformetastaticbonediseaseoftheextremities AT michaelmørkpetersen pretreatmentplasmail6andykl40andoverallsurvivalaftersurgeryformetastaticbonediseaseoftheextremities |
_version_ |
1721351255297622016 |